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ABSTRACT
Most cancer immunotherapies under present investigation are based on the belief 
that cytotoxic T cells are the most important anti-tumoral immune cells, whereas 
intra-tumoral macrophages would rather play a pro-tumoral role. We have challenged 
this antagonistic point of view and searched for collaborative contributions by tumor-
infiltrating T cells and macrophages, reminiscent of those observed in anti-infectious 
responses. We demonstrate that, in a model of therapeutic vaccination, cooperation 
between myeloid cells and T cells is indeed required for tumor rejection. Vaccination 
elicited an early rise of CD11b+ myeloid cells that preceded and conditioned the intra-
tumoral accumulation of CD8+ T cells. Conversely, CD8+ T cells and IFNγ production 
activated myeloid cells were required for tumor regression. A 4-fold reduction of 
CD8+ T cell infiltrate in CXCR3KO mice did not prevent tumor regression, whereas 
a reduction of tumor-infiltrating myeloid cells significantly interfered with vaccine 
efficiency. We show that macrophages from regressing tumors can kill tumor cells 
in two ways: phagocytosis and TNFα release. Altogether, our data suggest new 
strategies to improve the efficiency of cancer immunotherapies, by promoting intra-
tumoral cooperation between macrophages and T cells.
INTRODUCTION
T lymphocytes play an important role in restraining 
tumor development. Their infiltration in most human 
primary tumors is associated with better prognosis [1] 
and they seem to keep in check disseminated tumor cells 
and metastatic outgrowth [2]. Based on these notions, 
various types of T-cell based immunotherapies have 
been developed for treating cancer patients, and provided 
encouraging clinical results in the past few years. 
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In particular, melanoma patients have been successfully 
treated with high doses of IL-2 following adoptive transfer 
of TIL (Tumor infiltrating T lymphocytes) and lympho-
depletion by chemo- and radiotherapy [3]. Leukemic 
patients have been treated with autologous T cells 
engineered to express anti-CD19 chimeric receptors [4]. 
Other impressive results have been achieved in patients 
with advanced melanoma treated with a combination of 
anti-PD-1 and anti-CTLA-4 antibodies [5].
At the same time where these successes were 
obtained, the dominant point of view attributed a major 
role for T cells in the anti-tumor defense and most 
often restricted the contribution of macrophages to their 
suppressive and pro-tumoral potential. The temporal 
dimension of anti-tumoral immune responses is too rarely 
taken into account, which leads to neglect a major fact: 
cell states are dynamic. The immune system has been 
shaped by evolution so as to fight infections, not cancer, 
and efficient immune responses against viruses or bacteria 
invariably require a whole set of cellular interactions. 
When these pathogens are cleared, the immune responses 
are transient, with an acute and a recovery phase that are 
quite different, and both necessary for the efficacy and the 
safety of the system [6].
It is conceivable that a similar biphasic time-
response would apply for an immune reaction leading 
to tumor rejection. More than a century ago, W. Coley 
was one of the first to show that responses to infections 
could be followed by tumor regression, without clearly 
understanding why [7]. Adjuvants like CpG have been 
used to mimic such an inflammation in the context 
of tumors, but have often been considered mostly as 
an efficient way of maturing antigen-presenting cells 
to facilitate T cell priming. Such a view centered on 
T cells has overlooked the notion that innate cells like 
macrophages and neutrophils can also be efficient killers, 
for instance during the acute phase of anti-infectious 
responses.
A fundamental question that remains to be solved 
is how immune cells can reject tumor cells embedded in 
a tumor mass, in a connective network of stromal cells. 
In particular, the role of T lymphocytes in the rejection 
of such nodules is far from being understood. A classical 
view poses that T cells kill tumor cells directly in the 
tumor. Dynamic imaging revealed indeed that TCR-
transgenic T cells can be found close to dying tumor 
cells after adoptive transfer [8] and apoptosis induced by 
T cells in contact with tumor cells could be monitored 
directly in vivo [9]. It is difficult however to estimate 
how important these events are during tumor regression. 
One must take into account that this process is relatively 
slow, since one T cell needs several hours to kill one 
tumor cell [9]. This may explain why adoptive transfer of 
large numbers of T cells or chimeric receptor-transfected 
T cells is necessary to induce objective clinical responses 
in solid tumors (i.e., partial or complete tumor regression). 
Without adoptive transfer of such massive quantities of 
T cells, TIL are largely outnumbered by tumor cells, and it 
is highly unlikely that they would exhibit a massive direct 
cytotoxic effect. One must therefore consider more likely 
that T cells interact and cooperate with other immune cells 
that could gain cytotoxic potential against tumor cells to 
reject an established tumor.
It is striking that the ability of infiltrating T cells to 
secrete IFNγ appeared more crucial than their perforin-
dependent cytotoxicity in various cancer models [10, 11]. 
This observation suggested that other cytotoxic effector 
cells may indeed be activated due to IFNγ-producing 
T cells. Our group has previously shown that in advanced 
human tumors, T cells accumulate in the peri-tumoral 
stroma, and are rarely in direct contact with tumor 
cells [12]. It is thus likely that T cells mostly interact with 
other immune cells in the stroma. Intriguingly, frequent 
contacts between T cells and myeloid cells in tumors have 
been reported [13]. The functional consequences of such 
interactions remain unclear although they are generally 
considered to be non productive in progressing tumors 
[14, 15].
Previous studies have focused on progressing tumors 
and mechanisms of immune failure. By contrast, the goal 
of this work was to study the dynamics of an efficient anti-
tumoral immune response occurring in regressing tumors. 
Drawn from observations of immune responses during 
infections, we co-administered IFNα with a vaccine, 
in the TC1 tumor transplantation model. The vaccine 
was composed of a delivery system targeting dendritic 
cells, the non-toxic B-subunit of Shiga toxin coupled to 
HPV16 derived-E7 peptide (STxBE7 or E7-vaccine), and 
was used to elicit CD8+ T cells specific for E7 antigen 
expressed by the TC1-tumor cell line [16]. Vaccination 
of these tumor-bearing mice induced tumor regression, 
and by monitoring the influx of immune cells into tumors 
preceding regression, we have identified the key cellular 
and molecular players mediating the anti-tumor immunity. 
Using different experimental approaches, we provide 
evidence that, at least in this model and in the EG7 model, 
not only T cells but also activated, cytotoxic, tumor 
infiltrating myeloid cells are required for eliminating the 
tumor by TNFα production and phagocytosis of tumor 
cells. In these models, the key factor for the anti-tumoral 
action is not one cell type, but a dynamic and multi-step 
cooperation between two cell types.
RESULTS
The combination of E7-vaccine + IFNα induces 
systematic regression of TC1-tumors
C57BL/6J mice were transplanted with TC1 
tumor cells expressing the E7 protein from HPV. When 
tumor nodules reached 6 mm in diameter (~10 days), 
mice were treated with two peri-tumoral injections of 
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STxBE7- (termed E7-vaccine thereafter) and IFNα, one 
week apart. All mice showed a regression of TC1 tumors 
after the second injection (Figure 1A). Injection of IFNα 
alone did not halt the tumor growth and in mice treated with 
the vaccine alone tumors either stabilized or progressed, 
but almost never regressed after the boost (Figure 1A). 
These data show that the delivery of the vaccine together 
with IFNα (mimicking an infection near the tumor site) was 
optimal for inducing a systematic regression of tumors.
To follow the fate of TC1 tumor-cells in situ during 
tumor regression, mice were transplanted with TC1-GFP 
cells and tumors were analyzed by immunofluorescence 
on tumor slices [17]. In contrast to PBS-control mice, most 
tumor cells had been already eliminated in vaccinated mice 
at day 11, and replaced by cells with small nuclei, likely 
immune cells (Figure 1B). Imaging of whole tumor slices 
revealed that during stabilization at day 8 post-vaccination, 
tumor attack occurred from the periphery of the tumor 
(GFPneg area) where the vasculature was denser (Figure 1C 
and 1D). At day 10, the tumor was also attacked from the 
inside and finally by day 11, only a dense vascular network, 
no longer surrounded by GFP+ cells, was detected. These 
results confirmed that tumor vessels, which are required 
for tumor growth, are also the entry door for the Trojan 
horse, i.e. anti-tumor immune cells.
Influx of myeloid cells coincides with the onset 
of tumor regression and precedes infiltration by 
CD8+ T cells
As T cells were the primary target of the 
E7-vaccine, we first focused on the T cell response 
induced by vaccination. Transcriptomic analysis showed 
that expression of CD8A together with TBX21, IFNG 
and granzyme B progressively increased between day 
8 and day 11 in vaccinated animals (Figure 2A). These 
data indicate that the compound vaccine primed type 1 
cytotoxic CD8+ T cells. In situ, CD8+ T cells started to 
infiltrate the tumors by day 8 (Figure 2B). Surprisingly 
however, these CD8 T cells represented only a small 
portion of the CD45+ immune infiltrate detected at that 
time. While myeloid F4/80+ cells were already present in 
the tumor before treatment, we observed that they formed 
a much denser network around tumor cells in vaccinated 
mice compared to T cells (Figure 2B).
As tumor regression in mice treated with 
E7-vaccine + IFNα occurred in a predictable and 
reproducible manner (Figure 1A), it was possible to 
analyze the composition of the immune infiltrate before 
the onset of tumor regression. As shown in Figure 2C, 
immune cells were recruited to tumors of vaccinated 
mice in two distinct waves. A first rise in the CD45+ 
cells infiltrate occurred 5 days after priming, increasing 
from 5% to 12% (a significant increase, p = 0.03, Mann-
Whitney) and a second rise at day 11, when CD45+ 
cells represented up to 40% of viable cells in the tumor. 
The kinetics of CD11b+ cells followed the same pattern, 
with an early rise in CD11b+ cells 5 days after priming. 
At this time point, CD11b+ cells represented 8% of 
living cells, and constituted the vast majority of CD45+ 
cells in the tumor, whereas infiltrating CD8+ T cells were 
scarce and represented less than 1% of living cells. At the 
time when the tumor started to shrink (day 8–9), CD8+ 
T cells were still poorly represented (<5% of live cells) 
and were largely outnumbered by CD11b+ cells (which 
reached 15% of living cells). Nevertheless, there was a 
very small increase in CD8+ T cells at day 5 (from 0.2 
to 0.7% of living cells, right box Figure 2C) and these 
very rare CD8 T cells made frequent contact with myeloid 
cells as illustrated in Figure 2D. The density of CD8+ 
T cells became important only at late time points (day 10) 
when most of the tumor mass had already regressed. 
Such levels point out an indirect role of these cells, but 
not a role as major direct cytotoxic effector cells. Other 
immune cell subsets (CD4+ T cells, NK cells, Ly6G+ cells 
and γδT cells) remained at low levels (< 4% of living cells, 
Figure S1) at all time points. Altogether, these data show 
that tumor regression is associated with the presence of an 
early dense myeloid infiltrate in the tumor followed by a 
secondary accumulation of CD8+ T cells.
Both CD8+ TIL and infiltrating-F4/80+ cells are 
necessary for the tumor regression
CD8+ TIL were rare when the tumor started to 
shrink at day 8–9, despite a clear activation and infiltration 
later on. These data made us wonder whether CD8+ TIL 
were really essential for tumor regression. To address 
this question, CD8+ T cells were depleted at the time of 
regression, i.e. starting anti-CD8 i.p. injections on day 
5 after priming of TC1 tumor bearing mice. All tumors 
progressed in CD8-depleted animals (Figure 3A). In 
comparison, depletion of CD4 T cells did not inhibit 
tumor regression (Figure 3A). These results showed that 
the presence of CD8, but not that of CD4 T cells, was 
necessary for TC1 tumor regression.
Our transcriptomic analysis revealed that T-cell 
chemoattractants CXCL9 and CXCL10 were strongly 
upregulated after vaccination (Figure 3B). For this reason, 
we treated chemokine receptor 3 (CXCR3) knockout 
mice with the compound vaccine. Surprisingly, despite 
the marked 4-fold reduction in CD8+ T cell infiltrate 
(Figure 3C), TC1-tumors were quite efficiently rejected in 
vaccinated CXCR3KO mice (Figure 3D). Altogether, these 
results show that CD8+ T cells were important for TC1 
tumor regression, but they cannot be the sole cytotoxic 
effectors at the tumor site.
In order to investigate whether myeloid cells 
participate in the elimination of tumor cells in vivo, we 
treated TC1-tumor bearing mice with the compound 
vaccine and PLX3397, a CSF1-R signaling inhibitor [18]. 
This treatment led to an average 2-fold reduction of 
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Figure 1: TC1 tumor regression is triggered by injection of E7-vaccine + IFNα. C57BL6/J mice with TC1-tumors received 
various combinations of the E7-vaccine and IFNα. A. Tumor growth curves (individual mice, grey thin line; mean, dark thick line) are 
shown for each treatment. Red arrows : days of priming (day 0) and boost (day 7). B. The disappearance of tumor cells after vaccination is 
viewed 11 days after the priming as the disappearance of GFP+ cells (left) and as the decrease in the size of the nuclei (right), tumor nuclei 
being clearly larger (top) than nuclei of infiltrating immune cells (bottom). C. The disappearance of GFP+ cells (d8) begins in the tumor 
peripheral regions, D. which show a dense CD31+ vasculature (d8) and then affects more internal regions (d10), still the most vascularized 
ones. At d11, all GFP+ cells have disappeared.
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Figure 2: After vaccination with E7-vaccine + IFNα, an increase in the CD11b+ myeloid infiltrate precedes the 
accumulation of CD8+ T cells. A. Transcriptomic analysis of tumor infiltrate collected at various time points after vaccination show a 
progressive infiltration by type-1 effector CD8+ T cells. Time 0 corresponds to aged-matched PBS treated mice in which gene expression 
was quite stable during the follow up period. Statistical differences between individual time points and time 0 are shown. B. In control 
mice (top, PBS), the CD45+ infiltrate is mainly constituted of myeloid F4/80+ cells. After vaccination (bottom), regressing tumors (day 8) 
show a high density of CD45+ cells with both CD8+ T cells and F4/80+ cells. C. A detailed kinetics analysis by flow cytometry of CD45+, 
CD11b+ and CD8+ T cell infiltration after vaccination revealed an early rise in CD11b+ cells at day 5. A tiny increase of CD8 T cells, from 
0.2 to 0.7% of live cells in the tumor, occurred in this time frame (Inset). D. Two examples showing that these rare CD8+ T cells at day 5 
are in frequent interaction with F4/80+ cells.
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Figure 3: CD8+ T cells and myeloid-cell infiltrate are necessary for the tumor regression. A. Depletion of CD8 T cells 
prevented vaccine induced-tumor regression whereas depletion of CD4+ T cells did not. Tumor growth curves (mean of 8–12 individual 
mice) are shown for anti-CD8 Ab, anti-CD4 Ab and PBS-control littermates. B. Transcriptomic analysis shows that CXCL9 and CXCL10 
are upregulated in tumors after E7-vaccine+IFNα treatment. C. Reduction in vaccine-induced CD8+ T cell infiltrate in CXCR3KO mice 
compared to wild type mice. D. The growth of untreated TC1 tumors is unaffected by the KO of CXCR3. The vaccine treatment induced 
tumor regression in CXCR3KO just like in wild type littermates. E. After depletion of myeloid cells with PLX3397, the E7-vaccine+IFNα 
only elicited tumor stabilization, but not the tumor regression observed in mice fed with the control chow. Tumor regression was further 
blocked in mice treated with PLX3397 and anti-CD8 antibody. The change in tumor volume at various days post priming compared to 
tumor size at day 7 is shown (mean+/−SEM from 5 to 8 mice from 2–3 independent experiments). F. Depletion of myeloid cells with 
PLX3397 did not prevent the priming of Kb/E7-specific CD8 T cells by E7-vaccine, as quantified (left, one typical experiment) with 
dextramers on CD8 TIL from mock (top) or PLX3397-treated mice (bottom). Right : quantification done in 2 independent experiments.
Oncotarget7www.impactjournals.com/oncotarget
intra-tumoral CD11b+ cells within 2–3 days, with a 
significant reduction (~5-fold) in the proportion of F4/80+ 
cells (Figure S2). In these conditions, the tumors were 
stabilized, i.e., tumor regression no longer took place 
(Figure 3E). The simultaneous depletion of CD8+ T cells 
and F4/80+ cells abolished the efficacy of the vaccine. 
Of note, the combination of PLX3397 + anti-CD8 was 
not more efficient than anti-CD8 alone, because the 
anti-CD8 alone has already reached a full anti-vaccine 
efficiency. The frequencies of E7-specific CD8+ T cells 
infiltrating tumors were similarly high in macrophage-
depleted and control mice (~45% of CD8+ TIL on day 10, 
Figure 3F), which demonstrated that this treatment did 
not interfere with priming by the vaccine compound. It 
does not mean that the absolute number of CD8 T cells 
was not affected within the tumor, and in fact, it was 
decreased. This number results from the combination of 
the priming efficacy (which was kept intact) and of the 
efficiency in the recruitment of activated T cells in the 
tumor (whether E7-specific or not), which was diminished, 
as a direct or indirect result of the depletion of intra-
tumoral macrophages. Altogether, these results show that 
activated tumor-infiltrating myeloid cells are necessary for 
TC1-tumor cell elimination after vaccination, and that their 
action depends on the presence of anti-tumor CD8+ T cells.
To strengthen this conclusion, we used another way of 
reducing the intra-tumoral myeloid infiltrate, by implanting 
the tumors in CCR2-deficient mice, a condition well 
known to lower intra-tumoral monocyte recruitment [19]. 
Under these conditions, the intra-tumoral myeloid infiltrate 
was reduced, and so was the efficacy of the anti-tumoral 
vaccine (Figure S3A), which confirmed the necessity of 
myeloid cells for tumor regression. We investigated further 
whether anti-tumor myeloid cells could also be induced 
after immunization in additional tumor models. This 
turned out to be the case for EG7-tumors (EL4 thymoma 
cells expressing the chicken ovalbumin antigen) in which 
regression induced by STxB-OVA+IFNα is dependent on 
tumor-infiltrating myeloid cells (Figure S3B).
Dynamic cooperation between intra-tumoral 
CD8+ T cells and myeloid cells
We then analyzed in more details the phenotype and 
activation status of myeloid cells infiltrating regressing 
tumors. The CD11b+-infiltrate was mainly composed of 
CD11b+CD11cneg/lo and to a lesser extent of CD11b+CD11chi 
cells (~10%) (Figure 4A, dot plots). Expression of MHC II 
molecule was upregulated on CD11b+ cells after treatment 
(Figure 4A, histograms) indicating that these cells were 
activated. The CD11b+CD11cneg/lo infiltrate was composed 
of F4/80hi Ly6Clo cells (tumor-associated macrophages, 
TAM) and Ly6Chi F4/80lo cells (Ly6Chi, inflammatory 
monocytes) subsets (Figure 4B). In the absence of 
vaccination, a minority of Ly6Chi cells (~10%) expressed 
MHC II (Figure 4C). The level of MHC II on TAM was 
more variable along the same period in control mice (from 
20–40% MHC II+) suggesting that TAM could be locally 
activated by the growing tumor. However, vaccination 
induced a strong upregulation of MHC II expression at 
day 5 on Ly6Chi cells, concomitant with the early rise 
in myeloid cell number depicted in Figure 2C. Myeloid 
activation progressively increased to reach a maximum 
at day7 (~45% of Ly6Chi cells were MHC II+). MHC II 
expression on TAM was upregulated a bit later (~day 8) 
and was expressed by most of these cells (>80%) by day 
10. As illustrated in Figure 4D, a large fraction of CD11b+ 
cells expressed F4/80 in progressing tumors (PBS), 
whereas CD11b+ Ly6C+ cells were scarce. The major 
vaccination-induced increase in MHC II expression by 
F4/80+ cells is also shown. It is striking that activation of 
myeloid cells at day 7 did not occur in animals depleted 
of CD8+ T cells (Figure 4C), indicating that, despite 
their paucity at that time, vaccine primed-CD8+ T cells, 
that were frequently in close contact with F4/80+ cells at 
this early time point (Figure 2D), were necessary for the 
activation of infiltrating myeloid cells.
In an attempt to prevent some of the interactions 
between myeloid cells and T cells, IFNγKO mice were 
treated with the compound vaccine. In IFNγKO mice, 
tumor regression was prevented (Figure 4E) and the 
activation of myeloid cells (i.e., upregulation of MHC II) 
was markedly decreased compared to that observed in 
wild type mice (Figure 4F). These results indicate that 
efficient activation of F4/80+ myeloid cells, presumably 
by CD8+ T cells, is dependent on IFNγ.
We further characterized the activation status of 
myeloid cells infiltrating the tumor. The early increase 
in Ly6C gene expression in the tumor (before day 8) 
was accompanied with the expression of some myeloid 
markers upregulated during acute inflammation and 
commonly associated with M1-polarized macrophages 
(i.e. MHC IIhi, TNFαhi, CD86hi, Figure S4). However, the 
expression peak for several other markers of inflammatory 
cells was only reached later: see e.g. the abundance of 
CCL2 and CCR2+ cells (peaking at day 10), or iNOS, a 
key M1 marker whose expression peaked at day 11, when 
the tumors had already markedly regressed (Figure S4). 
We examined additional genes initially associated with M2 
cells (Fizz, IL-10, CD206, TGF-β), and observed an early 
and marked increase for some of them (Fizz, IL-10). These 
data underline that the local delivery of the vaccine+IFNα 
activated and reprogrammed the myeloid cell compartment 
with modulation of various genes that no more fit with the 
polarized M1/M2 schema as underlined recently [20].
To determine how tumor-infiltrating myeloid cells 
could contribute to tumor regression, we first looked at 
the production of TNFα by myeloid cells. About 12% of 
CD11b+ cells infiltrating regressing tumors in vaccinated 
mice spontaneously produced TNFα ex vivo, compared to 
3% of these cells in tumors from control mice (Figure S5). 
Stimulation with IFNγ+LPS in vitro revealed that the vast 
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Figure 4: Local activation of F4/80+ myeloid cells is promoted by the interactions with IFN-γ producing CD8 T cells.  
A. In progressing tumors (PBS, left), a fraction of CD11b+ cells also express CD11c and MHC II, but most CD11b+ cells do not express 
MHC II. After vaccination (right, d11 in this example), an increased fraction of CD11b cells express MHC II. B. Among CD11b+ myeloid 
cells, at least 3 populations may be distinguished based on F4/80 and Ly6C expression. C. After vaccination, MHC II expression is 
increased both in Ly6Chi cells and in F4/80hi Ly6Cneg TAM, except in mice depleted in CD8 (red asterix). D. Left : in progressing tumors 
(PBS), a large fraction of CD11b+ cells express F4/80 (different hues of purple). Middle: in progressing tumors, very few macrophages 
(F4/80+) are activated (MHC II+). MHC II+ F4/80neg cells are even rarer. Right : at day10, a majority of F4/80+ cells are MHC II+. E. The 
efficacy of E7-vaccine + IFNα treatment is abrogated in IFNγ KO mice (tumor growth curves with the mean+/-SEM of 7 mice from 2 
independent experiments). F. Activation of Ly6Chi cells and TAM was prevented at day 10 after priming in IFNγ KO mice (mean+/-SEM 
of 3 mice from 3 independent experiments).
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majority of CD11b+ cells (>80%) from vaccinated mice 
readily produced TNFα. These results are suggestive of 
a cytotoxic potential for these myeloid cells infiltrating 
regressing tumors. In co-culture experiments, TC1-GFP+ 
cells were effectively killed by F4/80+ cells purified from 
regressing tumors, as detected by the reduced density of 
adherent TC1 cells (Figure 5A and 5B). In sharp contrast, 
a dense network of healthy TC1-GFP+ cells was observed 
in co-cultures with myeloid cells from progressing tumors. 
Importantly, we could show that the cytotoxic activity of 
myeloid cells was partially blocked in the presence of an 
anti-TNFα antibody (Figure 5A and 5B). Of note, in this 
in vitro assay, CD8 T cells, purified from tumor-bearing-
mice that were vaccinated 8 days earlier, did not modify 
the cytotoxicity of purified macrophages. CD8 T cells were 
added at densities 10 times lower than that of monocytes/
macrophages, which corresponds to in vivo ratios (data 
not shown). The CD8-macrophage cooperation observed 
in vivo presumably required precise spatio-temporal 
constraints that were not recapitulated in the in vitro assay.
Next, we attempted to visualize directly dying 
tumor cells in the tumor tissue of vaccinated animals: in 
tumors examined 24 h after the boost, most dead (PI+) 
tumor cells were found surrounded by F4/80+ myeloid 
cells (Figure 5C, left panel), at several cell diameters 
from CD8+ T cells. In addition, we frequently observed 
examples of living (still green) but compacted TC1 cells 
fully engulfed by myeloid cells (Figure 5C, right panel). 
These results revealed that at least a fraction of myeloid 
cells that infiltrate regressing tumors were likely to be 
cytotoxic for TC1-tumor cells by mechanisms that could 
include TNFα release and phagocytosis.
To gain further insight into the anti-tumoral in vivo 
mechanisms, we blocked potential myeloid effector 
molecules, TNFα and NO, in vaccinated TC1-bearing 
mice. As suggested by in vitro experiments, an anti-TNFα 
treatment, but not L-NAME treatment (an inhibitor of NO 
production), partially inhibited vaccination-induced tumor 
regression (Figure 5D).
Altogether, these results show that a multi-step 
CD8+ T cell / myeloid-cell cooperation takes place within 
the tumor microenvironment after vaccination : this 
dynamic cooperation allows that vaccine-elicited CD8 
T cells and activated cytotoxic myeloid-cells contribute 
to tumor regression.
DISCUSSION
CSF-1 overexpression and high densities of intra-
tumoral macrophages are often considered as indicators 
of poor prognosis for cancer patients [21, 22]. Even if this 
is true in progressing tumors, this should not hide the fact 
that appropriately stimulated macrophages may directly or 
indirectly slow down tumor growth [23, 24]. Here, we have 
shown that after an appropriate stimulation, intra-tumoral 
macrophages - in cooperation with T cells - contributed 
efficiently to tumor regression. This apparent discrepancy 
(pro- or anti-tumoral macrophages) illustrates the importance 
of taking into account the interactions between different 
immune cells, and the temporal dimension of an immune 
response, which allows the apparently same cell type to 
exert quite different effects [6].
More precisely, we have shown that rejection of 
TC1 and EG7 solid tumors induced by a vaccine+IFNα 
requires the participation of activated-myeloid cells. Our 
study highlights the anti-tumoral potential of macrophages 
during an acute immune response induced in tumors. Such 
an anti-tumoral potential has already been reported, but 
after a targeted macrophage activation [23, 25, 26] and 
rarely following cooperation with T cells [27–29]. What 
was the appropriate monocyte/macrophage stimulation 
in our experiments? Both components of the vaccine 
(IFNα and STxB-vaccine) probably contributed to it. 
IFNα is known to be able to trigger an inflammatory 
response [29, 30] and IFN type I downstream signaling 
was recently associated with efficient antitumor activity in 
some chemotherapy-induced immune responses [31]. The 
contribution of STxB-vaccine to the appropriate myeloid 
stimulation could have lied in the activation of a CD8+ 
T cell response associated with an increase in IFNγ. IFNγ 
is a potent stimulus for myeloid cells, especially when 
combined with CD40 stimulation [32]. Such a coupled 
IFNγ plus CD40 stimulation may occur during cognate 
T cell-myeloid cell close contacts. The existence of such 
a phenomenon is suggested by different observations. 
1) Signs of myeloid cell activation (MHC II and CD86 
expression, Figure 4C and S4) took place with the first 
wave of T cell infiltration (5 days after the priming), 
quantitatively quite modest, but potentially qualitatively 
important. 2) Intra-tumoral T cell-macrophage interactions 
were easily observed at day 5, despite the rarity of 
infiltrating T cells at that time (Figure 2C and 2D). 
3) T cells played an important role even when they were 
not abundant, e.g., in CXCR3 KO mice. 4) Macrophage 
activation, measured by MHC II expression, did not occur 
under conditions in which activated-T cells were absent 
(e.g., after CD8+ T cell depletion, Figure 4C). 5) IFNγ 
played a key role in vaccine efficacy, potentially and at 
least in part, through T cell-induced macrophage activation 
(Figure 4E and 4F). This T cell / myeloid cells cooperation 
is reminiscent of the activation of host macrophages 
reported after adoptive cell transfer of IFNγ-producing 
T cells [10, 28, 33, 34, 35]. However, here, it has not 
been observed as a result of the massive introduction of 
IFNγ-producing T cells but simply as a result of T-cell 
stimulation in parallel to mimicking a local infection.
The efficient priming of E7-specific CD8+ T cells, 
which is necessary to achieve tumor regression, was 
made possible by the use of the STxB-vaccine that favors 
induction of CD8+ T cells [36, 37], in the absence of a 
marked CD4 activation. In our compound vaccine, it is 
likely that CD8+ T cell help and recruitment were provided 
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by IFNα-dependent responses. There is an apparent 
paradox in the fact that tumor regression was blocked by 
complete CD8+ T cells depletion with anti-CD8 antibodies, 
but remained unaffected when tumor-infiltrating CD8 
T cells were markedly depleted in CXCR3KO mice. 
Different and non-exclusive explanations are possible. 
One is that the consequences of a full depletion are quite 
distinct from those of a partial depletion, especially if 
T cells act as a trigger or an amplifier for other cytotoxic 
effectors, as discussed below. Secondly, tumor regression 
could be conditioned by CD8+ T cell/myeloid cell 
interactions taking place in tumor-draining lymph nodes, 
a phenomenon not expected to be affected in CXCR3 
KO mice. Finally, CD8+ T cells may include two subsets, 
Figure 5: Activated-myeloid cells contribute to the killing of TC1-tumor cells by TNF-α release. A. TC1-GFP+ tumor 
cells were co-cultured with F4/80+ cells isolated from tumors at day 8. Contrary to control tumors (lower left), myeloid cells from vaccine 
treated mice (right panels) were cytotoxic for tumor cells (disappearance of GFP labeling, loss of tumor cells). Cytotoxic activity of F4/80+ 
cells was blocked in the presence of anti-TNFα Ab (lower right). Representative examples out of 3 independent experiments are shown. 
B. Quantification of the living cells, measured in one out of 3 independent experiments. The apparent fraction of living adherent TC1 cells 
(fraction of the image occupied by GFP+ cells, measured in 6–17 images per condition) is shown in the various conditions. C. Example of 
dying tumor cells in tumors of vaccinated mice 1 day after the boost, where PI+ GFP− cells were found in close contact with F4/80+ cells 
(left) or living tumor cells (small round GFP++ cells) were found within F4/80+ cells (right). D. The efficacy of E7-vaccine + IFNα treatment 
is partially reduced in anti-TNFα treated mice but was not affected by NO inhibition with L-NAME.
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one of which being independent of CXCR3 ligands, for 
instance depending on CCL5 for its infiltration.
After treatment with the compound vaccine, the 
first sign of local anti-tumoral response was an increase in 
CD11b+ myeloid cells, associated with high intra-tumoral 
levels of Ly6C and CCL2 gene expression, typical of the 
appearance of classical/inflammatory monocytes recruited 
by CCL2/CCR2 [38]. This recruitment is functionally 
important, since we have shown that TC1-tumor regression 
was blocked in CCR2KO mice. A crucial difference with 
monocytes infiltrating progressing tumors [39, 40] is 
the fact that the vaccination promoted an inflammatory 
microenvironment. In our settings, IFNα induces the 
production of CXCL10. The fact that the depletion of 
myeloid cells with PLX3397 decreases the T cell infiltrate 
strongly suggests that myeloid cells act upstream to attract 
T cells to the tumor. In return, the coexistence of a small 
but decisive amount of T cells at the time of myeloid cell 
infiltration might have driven the swift up regulation of 
MHC class II, CD86 and TNFα in myeloid cells. The 
emergence of such activated myeloid cells is reminiscent 
of the TipDC observed after bacterial infection [41] or the 
CD11b+CD11c+Ly6Chi cells infiltrating tumors treated with 
anthracycline [42]. Note that the coexpression of F4/80 
and CD11c in a fraction of activated intra-tumoral myeloid 
cells obscures the distinction between macrophages and 
dendritic cells in this microenvironment (contrary to the 
situation observed in lymph nodes). In order to mimic the 
local activation of macrophages by infiltrating T cells, 
we performed intra-tumoral injections of an anti-CD40 
agonist antibody + IFNγ. However, this treatment elicited 
regression / stabilization in only a minority (4 out of 12) 
of TC1 tumors (data not shown). Thus, this combined 
treatment did not faithfully mimic the spatio-temporal 
features of the synchronized recruitment of T cells and 
monocytes elicited by the vaccine compound.
Myeloid cells could mediate cytotoxic and/or 
cytostatic effects on malignant cells. Our in vitro and 
in vivo data show that F4/80+ cells from vaccinated mice 
can directly kill TC1 tumor cells by mechanisms that 
involve phagocytosis and TNFα. In previous studies with 
anti-tumoral macrophages, NO, ROS or TNFα were shown 
to slow down tumor growth in vitro, which may reveal 
cytostatic rather than cytotoxic effects [10, 26, 43, 44]. 
Even if iNOS+ macrophages could be necessary in other 
settings for an optimal recruitment of T cells into tumors 
[24], in our system of vaccination against TC1 tumors, NO 
production was dispensable for vaccine-induced tumor 
regression.
When macrophages are considered exclusively 
as pro-tumoral cells, it is logical to aim at depleting 
them so as to facilitate the efficacy of cytotoxic agents 
or cytotoxic T cells [18, 45]. It has been reported that 
macrophage stimulation with poly I:C triggers an 
antitumor cytotoxicity [23], and that local low-dose 
gamma irradiation activated TAM and resulted in the 
recruitment of cytotoxic T cells [24]. We propose a more 
global view, in which myeloid cells, when appropriately 
stimulated, can be activated by primed T cells and can 
support those T cells to directly eliminate tumor cells. The 
existence of a bi-directional interaction between myeloid 
cells and T cells in the tumor, including attraction and 
activation, warrants further investigations.
Our findings contrast with recent reports in 
which myeloid cells reduce the anti-tumoral action of 
chemotherapy or adoptive T cell transfer [18, 45, 46]. 
This paradox most probably reflects the heterogeneity of 
the tumor types and microenvironments and the need to 
identify which therapies or treatment-schedule conditions 
the generation of anti-tumor myeloid cells.
As mentioned earlier, a few studies report on the 
existence of anti-tumoral macrophages. However, to our 
knowledge, this is the first report in which an efficient 
anti-infectious response is used as a conceptual model 
for an anti-tumoral response. In a typical anti-infectious 
response the local alert of resident macrophages results 
in macrophage activation and recruitment of more innate 
cells followed by T cell priming and antigen-specific 
T cell recruitment to the infection site. By making the 
appropriate spatio-temporal measurements, we were able 
to describe an anti-tumoral response with the initial local 
activation of myeloid cells, involving a small amount of 
tumor-infiltrating T cells, which clearly preceded a more 
massive T cell infiltrate immediately after the vaccination 
boost. Our study highlights that the anti-tumoral myeloid 
cells should not be viewed as a static subset entirely 
distinct from the pro-tumoral ones, but rather as a dynamic 
population resulting from an influx of myeloid cells and 
from their intra-tumoral differentiation. The kinetics of 
these fluxes would deserve a whole additional study.
MATERIALS AND METHODS
Animal studies
C57BL/6J mice were purchased from Charles River 
laboratories. Mice were maintained in the Cochin Institute 
SPF animal facility. Animal care was performed by expert 
technicians in compliance with the Federation of European 
Laboratory Animal science association and under the 
approval of the animal experimentation ethics committee 
of Paris Descartes (CEEA34.ED.042.12).
The TC1 cell line, and for some experiments the 
EG7 cell line, were maintained in culture in complete 
RPMI, including 10% FCS (GE Healthcare), antibiotics 
(Penicillin 50U/ml, Streptomycin 50 μg/ml, GIBCO), 
L-Glutamine (4 mM, GIBCO) and Sodium Pyruvate 
(1 mM, GIBCO). The TC1-GFP cell line was generated 
by infection of TC1 cells with a GFP-lentivirus. 
Lentiviral production was obtained by transient calcium-
phosphate co-transfection of the 293T cell line with 
the TRIP∆U3-EF1α vector, the p8.91 encapsidation 
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vector (∆Vpr∆Vif∆Vpu∆Nef), and a vesicular stomatitis 
virus-G protein (VSV-G) envelop expression plasmid 
(pHCMV-G). GFP was expressed by >90% of TC1 cells.
Eight weeks-old C57BL/6J were inoculated in the 
flank with 105 TC1 cells. When tumors reached a diameter 
of 6 mm (~10 days), mice were primed (= day 0) with 
a peritumoral injection of 20 μg of E7-vaccine (STxBE7 
vaccine, [16]) and 6 × 105U of IFNα4 [47] in a total 
volume of 200 μl. Littermates were injected with PBS as 
control. The next day, vaccinated mice received the same 
dose of IFNα. This protocol was repeated one week later 
(boost, = day7). For some experiments, IFNγKO (kindly 
provided by O. Lantz, Institut Curie, Paris, France), 
CXCR3KO mice (SigN, Singapore) and CCR2KO mice 
(kindly provided by T. Henry, CIRI Inserm, Lyon, France) 
were used.
For CD8+ T cell depletion, 200 μg of anti-CD8 
antibody (BioXcell, clone 53–6.72) were injected every 
2 days starting on day 5 after the priming. Anti-CD4 
antibody (BioXcell, clone GK1.5, 150 μg) or anti-TNFα 
(BioXcell, clone TN3–19.12, 300 μg), were injected 
every 3 days starting at the time of priming. Macrophage 
depletion was performed with PLX3397 (Plexxikon), a 
CSF1-R signaling inhibitor. Mice were fed with chow 
containing PLX3397, or control chow, right after the 
priming. With such a treatment, macrophage depletion 
is expected to begin 2–3 days later [18]. Nitric oxide 
(NO) was blocked with L-NAME added in the drinking 
water (500 μg/ml, N5751 Sigma,) the day of priming and 
renewed every 2 days.
Analysis of the tumor infiltrate by multicolor 
flow cytometry
Fresh TC1 tumors were dissociated mechanically 
and incubated 30 minutes at 37°C with DNaseI 
(100 μg/ml, Roche) and collagenase (1 mg/ml, Roche). 
The cell suspension was filtered on a 40 μm sieve, and 
rinsed several times with PBS 2% FCS 0.5 mM EDTA. 
Cells (4 × 106) were stained in 96-wells round bottom 
plates with dead/live staining (Blue fluorescent reactive 
dye, Invitrogen) during 20 minutes at room temperature. 
Fc receptors were blocked with anti-FCR (anti-CD16 CD-
32 at 5 μg/ml, BD Pharmingen). Then, cells were either 
stained with biotinylated anti-Ly6C (myeloid analysis) or 
biotinylated anti-TCRβ (lymphoid analysis), for 15 minutes 
at 4°C with agitation. After 2 washes in PBS 2% FCS, cells 
were stained with antibodies CD45.2-PerCP-Cy5.5, CD11b-
APC, CD11c-PE-Cy7, NK1.1-PE, streptavidin-Pac Blue and 
Ly6G-FITC (for myeloid staining), antibodies CD45.2-APC, 
IA/IE-PE, CD11b-FITC, CD11c-PE-Cy7, streptavidin-
Pacific Blue and F4/80-PerCP-Cy5.5 (for macrophages 
and MHC II staining), or with antibodies CD45.2-APC, 
CD4-Pacific Blue, CD8-APC-H7, streptavidin-PE-Cy7, 
CD19-FITC, NK1.1-PerCP-Cy5.5 and anti-TCRβ-PE 
(for lymphoid staining). Antibodies were purchased from 
BD Pharmingen, except for the CD11b-APC antibody, 
which was purchased from eBiosciences. For detection of 
E7-specific CD8+ T cells, cell suspensions were stained with 
PE-Kb/E7 dextramer (JA2195, Immudex) for 40 minutes at 
4°C, followed by staining with cell surface markers for CD8, 
CD4, NK, CD19 and CD45. After washing in PBS, cells 
were fixed in 1% PFA, stored at 4°C, and acquired the next 
day with LSR II flow cytometer (BD Bioscience).
Immunofluorescence
Tumor pieces were fixed overnight with 
Periodate-Lysine-Paraformaldehyde [48] at 4°C and 
Immunofluorescence on tumor slices was performed 
as previously described [17, 49]. Immunostaining was 
performed by first blocking Fc receptors with anti-FCR (BD 
Pharmingen), then staining for 1 h RT or at 4°C overnight 
was performed with primary antibodies specific for 
CD8-PerCP, CD45-APC, IA-IE-PE, CD11b-FITC, Ly6C-
APC, CD31-biotin (all from BD Pharmingen), fibronectin, 
gp38/podoplanin, F4/80-biotin (all from Biolegend) or F4/80-
PE (AbD Serotec). Immunodetection was performed using 
anti-Rat or anti-rabbit antibodies coupled to 488, 568 or 647 
(BD Pharmingen) and streptavidin- Alexa Fluor 488 or 647 
(Invitrogen). Slices were then counter-stained with Hoechst 
for 10 min at room temperature. Antibodies were diluted in 
PBS, 0.5% BSA, 2% human serum. Images were obtained 
with a spinning disk microscope equipped with a CoolSnap 
HQ2 camera (Photometrics) and a 20x and a 63x objective. 
All images were acquired with MetaMorph 7 imaging 
software (Molecular Devices) and analysed with ImageJ. 
For staining of dying cells in vivo, vaccinated TC1-GFP 
bearing mice received an intra-tumoral injection of 
propidium iodide (1 mg/ml) and were sacrificed 30 min later.
Transcriptomic analysis
Tumor RNA was extracted using RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions 
and gene expression was analyzed with the nanostring 
technology. 36 lanes of Nanostring data were processed 
using Accelrys Pipeline Pilot. The geometrical mean of 
the positive control probe counts were computed for each 
lane and a scaling factor computed for each lane being 
the average of the geometrical means of all lanes A was 
divided by the geometrical mean of that particular lane. 
This scaling factor was then applied to all probe counts 
for all lanes as a means to normalize for the technical 
variability of the platform. The house keeping genes 
ACTB, GAPDH and RPL4 were then used to normalize 
for any RNA loading differences. This was performed 
in the same manner as the positive control probes where 
the scaling factor was computed from the geometrical 
mean of the housekeeping genes. The positive control 
and housekeeping normalized counts were then 
logarithmically transformed and used for all subsequent 
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analysis. One way ANOVAs were used to test if any of 
the probes counts were significantly different between 
sample groups. Pearson correlations were to identify pairs 
of correlating genes. All statistical testing was done using 
the R statistical language version 2.15.2. p < 0.05 were 
deemed to be statistically significant. Multiple testing 
corrections were performed for all tests using the method 
of Benjamini and Hochberg. Visualization of the data and 
test results were done using GraphPad Prism 5.
Cytotoxic assay with tumor-derived 
 myeloid cells
F4/80+ myeloid cells were purified from tumor cell 
suspensions using F4/80-biotin Ab (eBioscience), and 
streptavidin-beads before sorting with Automacs (Miltenyi 
Biotec). Purified cells were treated 5 minutes at 37°C 
with DNase (100 μg/ml) to remove cell debris. F4/80+ 
cell suspension were > 90% pure. Purified myeloid cells 
(2 × 105) were added on the top of a monolayer of TC1-
GFP+ cells (2 × 104 cells) and co-cultured for 48 h at 37°C. 
TNFα was blocked with anti-TNFα at 10 μg/ml (Abcam). 
Images were obtained with an inverted microscope 
(TE2000-E; Nikon) equipped with a 20x objective, and 
Metamorph imaging software.
Statistics
Unless otherwise indicated, results are expressed 
as means ± SEM of 3 to 6 mice. All experiments were 
repeated at least twice, yielding similar results. Data 
were analyzed with GraphPad Prism5 software. p values 
were calculated by the unpaired Student’s t test or One-
way ANOVA and Tukey test for multiple comparison. 
Values ≤ 0.05 were considered significant. *p < 0.05; 
**p < 0.01; ***p < 0.001.
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